PA8631201A1 - Compuestos de metil-aril o heteroaril-amida sustituida - Google Patents

Compuestos de metil-aril o heteroaril-amida sustituida

Info

Publication number
PA8631201A1
PA8631201A1 PA20058631201A PA8631201A PA8631201A1 PA 8631201 A1 PA8631201 A1 PA 8631201A1 PA 20058631201 A PA20058631201 A PA 20058631201A PA 8631201 A PA8631201 A PA 8631201A PA 8631201 A1 PA8631201 A1 PA 8631201A1
Authority
PA
Panama
Prior art keywords
similar
heteroaril
amida
aril
methyl
Prior art date
Application number
PA20058631201A
Other languages
English (en)
Inventor
Yoshiyuki Okumura
Kana Kon
Kazunari Nakao
Yukari Matsumoto
Hiroki Koike
Tatsuya Yamagishi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982397&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8631201(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of PA8631201A1 publication Critical patent/PA8631201A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Abstract

ESTA INVENCION PROPORCIONA UN COMPUESTO DE FORMULA (l): EN LA QUE X REPRESENTA UN ATOMO DE CARBONO O SIMILIAR: Y REPRESENTA IMINO, O SIMILAR: R1 REPRESENTA UN GRUPO ALQUILO QUE TIENE DE I a 6 ATOMOS DE CARBONO O SIMILAR; R2 y R3 INDEPENDIENTEMENTE REPRESENTAN UN ATOMO DE HIDROGENO O SIMILAR. ESTOS COMPUESTOS SON UTILES PARA TRATAR ESTADOS PATOLOGICOS MEDIADOS POR PROSTAGLANDINA TALES COMO EL DOLOR, O SIMILAR, EN UN MAMIFERO. ESTA INVENCION TAMBIEN PROPORCIONA UNA COMPOSICION FARMACEUTICA QUE COMPRENDE EL COMPUESTO ANTERIOR.
PA20058631201A 2004-05-04 2005-04-27 Compuestos de metil-aril o heteroaril-amida sustituida PA8631201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56808804P 2004-05-04 2004-05-04

Publications (1)

Publication Number Publication Date
PA8631201A1 true PA8631201A1 (es) 2005-11-25

Family

ID=34982397

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058631201A PA8631201A1 (es) 2004-05-04 2005-04-27 Compuestos de metil-aril o heteroaril-amida sustituida

Country Status (29)

Country Link
US (2) US7534914B2 (es)
EP (1) EP1756042B8 (es)
JP (1) JP4054368B2 (es)
KR (1) KR20070006891A (es)
CN (1) CN1950333A (es)
AP (1) AP2006003785A0 (es)
AR (1) AR048642A1 (es)
AU (1) AU2005238291A1 (es)
BR (1) BRPI0510666A (es)
CA (1) CA2565813C (es)
CR (1) CR8730A (es)
DO (1) DOP2005000071A (es)
EA (1) EA200601847A1 (es)
EC (1) ECSP066968A (es)
ES (1) ES2461265T3 (es)
GT (1) GT200500101A (es)
IL (1) IL178676A0 (es)
MA (1) MA28571B1 (es)
MX (1) MXPA06011555A (es)
NL (1) NL1028947C2 (es)
NO (1) NO20065578L (es)
PA (1) PA8631201A1 (es)
PE (1) PE20060306A1 (es)
SV (1) SV2005002102A (es)
TN (1) TNSN06358A1 (es)
TW (1) TW200536541A (es)
UY (1) UY28877A1 (es)
WO (1) WO2005105732A1 (es)
ZA (1) ZA200608393B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2619472A1 (en) 2005-09-19 2007-03-29 Teva Pharmaceutical Industries Ltd. Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the new synthesis of (s)-pregabalin
DE102005062966A1 (de) * 2005-12-28 2007-07-05 Basf Ag Verfahren zur Herstellung von (R)- und (S)-4-(Ammoniumethyl)benzoesäuremethylester-sulfat
US8008062B2 (en) 2005-12-28 2011-08-30 Basf Se Production of (R)- and (S)-4-(1-aminoethyl) benzoic acid methyl ester sulfate by lipase acylation of racemic 4-(1-aminoethyl) benzoic acid methyl ester and sulfuric acid precipitation
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
AU2007283404B2 (en) * 2006-08-11 2013-04-18 Merck Canada Inc. Thiophenecarboxamide derivatives as EP4 receptor ligands
US20080167377A1 (en) 2006-12-15 2008-07-10 Alessandra Gaiba Novel compounds
WO2009005076A1 (ja) 2007-07-03 2009-01-08 Astellas Pharma Inc. アミド化合物
GB0721611D0 (en) * 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
US8598355B2 (en) * 2008-05-14 2013-12-03 Astellas Pharma Inc. Amide compound
US20100087525A1 (en) * 2008-06-23 2010-04-08 Lilach Hedvati Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
JPWO2010087425A1 (ja) 2009-01-30 2012-08-02 国立大学法人京都大学 前立腺癌の進行抑制剤および進行抑制方法
CA2754702C (en) 2009-04-22 2016-06-07 Yukinori Take Selective ep4 antagonistic substance for treatment of cancer
CA2789665C (en) * 2010-02-22 2020-06-16 Raqualia Pharma Inc. Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
RU2606510C2 (ru) * 2010-09-21 2017-01-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция
ES2545110T3 (es) 2010-12-10 2015-09-08 Rottapharm Biotech S.R.L. Derivados de piridinamida como antagonistas del receptor EP4
JP5813223B2 (ja) 2011-07-04 2015-11-17 ロッタファーム バイオテック エス アール エル Ｅｐ４レセプターアンタゴニストとしての環状アミン誘導体
WO2013032971A1 (en) 2011-08-29 2013-03-07 Ticona Llc Melt-extruded substrate for use in thermoformed articles
US9074133B2 (en) 2011-08-29 2015-07-07 Ticona Llc Thermotropic liquid crystalline polymer with improved low shear viscosity
TW201319118A (zh) 2011-08-29 2013-05-16 Ticona Llc 低熔融黏度液晶聚合物之熔融聚合
JP2014525498A (ja) 2011-08-29 2014-09-29 ティコナ・エルエルシー 高流動性液晶ポリマー組成物
WO2013032967A1 (en) 2011-08-29 2013-03-07 Ticona Llc Cast molded parts formed form a liquid crystalline polymer
CN103764793B (zh) 2011-08-29 2016-09-14 提克纳有限责任公司 高流动液晶聚合物组合物
TW201319022A (zh) 2011-08-29 2013-05-16 Ticona Llc 芳族醯胺化合物
US8906258B2 (en) 2011-08-29 2014-12-09 Ticona Llc Heat-resistant liquid crystalline polymer composition having a low melting temperature
WO2013032974A1 (en) 2011-08-29 2013-03-07 Ticona Llc Solid-state polymerization of a liquid crystalline polymer
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
WO2014130275A2 (en) 2013-02-22 2014-08-28 Ticona Llc High performance polymer composition with improved flow properties
US10391086B2 (en) 2013-03-19 2019-08-27 Askat Inc. Use of EP4 receptor antagonists in the treatment of cartilage disease
CN107496421A (zh) * 2013-03-19 2017-12-22 株式会社ＡｓｋＡｔ Ep4受体拮抗剂在软骨疾病的治疗中的用途
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
JP6625050B2 (ja) 2013-06-07 2019-12-25 ティコナ・エルエルシー 高強度サーモトロピック液晶ポリマー
ES2669977T3 (es) 2013-06-12 2018-05-29 Kaken Pharmaceutical Co., Ltd. Derivado de 4-alquinilimidazol y medicamento que lo comprende como ingrediente activo
EP3083562B1 (en) 2013-12-17 2017-09-27 Eli Lilly & Company Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
US10342785B2 (en) * 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
PL3625222T3 (pl) 2017-05-18 2021-12-27 Idorsia Pharmaceuticals Ltd Pochodne fenylu jako modulatory receptora pge2
AR111874A1 (es) 2017-05-18 2019-08-28 Idorsia Pharmaceuticals Ltd Derivados de pirimidina
ES2929309T3 (es) 2017-05-18 2022-11-28 Idorsia Pharmaceuticals Ltd Derivados de benzofurano y benzotiofeno como moduladores del receptor PGE2
ES2894124T3 (es) 2017-05-18 2022-02-11 Idorsia Pharmaceuticals Ltd Derivados de indol N-sustituidos
CN110612299A (zh) 2017-05-18 2019-12-24 爱杜西亚药品有限公司 作为pge2受体调节剂的嘧啶衍生物
SK592017A3 (sk) * 2017-07-04 2019-01-08 Saneca Pharmaceuticals A. S. Spôsob prípravy morfínanových zlúčenín
KR102507987B1 (ko) 2017-09-22 2023-03-21 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
WO2022037601A1 (zh) * 2020-08-18 2022-02-24 武汉人福创新药物研发中心有限公司 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在制备治疗癌症和炎症药物中的用途
EP4245301A1 (en) 2020-11-13 2023-09-20 ONO Pharmaceutical Co., Ltd. Cancer treatment by combined use of ep4 antagonist and immune checkpoint inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19648793A1 (de) 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
BR9810733A (pt) 1997-04-04 2000-09-12 Pfizer Prod Inc Derivados de nicotinamida
US6211197B1 (en) * 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
JP2003500385A (ja) 1999-05-24 2003-01-07 コア・セラピューティクス，インコーポレイテッド Ｘａ因子阻害剤
US6924391B2 (en) 2000-05-11 2005-08-02 Bristol-Myers Squibb Company Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors
ATE293109T1 (de) 2001-01-31 2005-04-15 Pfizer Prod Inc Nikotinsäureamid-derivate und ihre mimetika als inhibitoren von pde4-isozyms
JP4529119B2 (ja) 2001-08-09 2010-08-25 小野薬品工業株式会社 カルボン酸誘導体化合物およびその化合物を有効成分として含有する薬剤
EP1438973A4 (en) 2001-10-05 2005-07-13 Ono Pharmaceutical Co MEANS FOR THE TREATMENT OF STRESS-RELATED DISEASES WITH MITOCHONDRIENE BENZODIAZEPINE RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
IL178676A0 (en) 2007-02-11
GT200500101A (es) 2005-12-12
ZA200608393B (en) 2008-05-28
NO20065578L (no) 2007-01-12
TNSN06358A1 (fr) 2008-02-22
MA28571B1 (fr) 2007-05-02
US7534914B2 (en) 2009-05-19
CA2565813A1 (en) 2005-11-10
CR8730A (es) 2006-11-30
JP2007536366A (ja) 2007-12-13
EP1756042B1 (en) 2014-02-12
NL1028947A1 (nl) 2005-11-07
ES2461265T3 (es) 2014-05-19
US20090163558A1 (en) 2009-06-25
AP2006003785A0 (en) 2006-10-31
PE20060306A1 (es) 2006-04-14
EA200601847A1 (ru) 2007-04-27
UY28877A1 (es) 2005-12-30
SV2005002102A (es) 2005-12-13
BRPI0510666A (pt) 2007-12-04
WO2005105732A8 (en) 2007-04-19
AU2005238291A1 (en) 2005-11-10
JP4054368B2 (ja) 2008-02-27
WO2005105732A1 (en) 2005-11-10
AR048642A1 (es) 2006-05-10
CA2565813C (en) 2010-10-26
EP1756042A1 (en) 2007-02-28
MXPA06011555A (es) 2006-12-15
DOP2005000071A (es) 2005-11-30
TW200536541A (en) 2005-11-16
US8084476B2 (en) 2011-12-27
ECSP066968A (es) 2006-12-29
CN1950333A (zh) 2007-04-18
US20050267170A1 (en) 2005-12-01
NL1028947C2 (nl) 2006-04-10
EP1756042B8 (en) 2014-06-04
KR20070006891A (ko) 2007-01-11

Similar Documents

Publication Publication Date Title
PA8631201A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida
SV2006002103A (es) Compuestos de aril- o heteroarilamida ortosustituidos ref. pc32242a
PA8610801A1 (es) Compuestos de aril o heteroaril amida
ECSP034642A (es) Derivados de tetralona como agentes antitumorales
CR9663A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
BRPI0507968A (pt) oxidação de compostos orgánicos a ph alto
UY28144A1 (es) Agentes terapéuticos
GT200500157A (es) Difenilimidazopirimidina e imidazol aminas como inhibidores de beta-secretasa
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
GT200500242A (es) Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
ECSP088765A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
BRPI0409680A (pt) análogos de fosfonato anti-cáncer
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
UY29412A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
PA8632601A1 (es) Derivados de pirimidina para tratar el crecimiento celular anómalo
UY29197A1 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos
PA8576101A1 (es) Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
PA8576001A1 (es) "difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion , medicamentos que comprenden estos compuestos y su uso".
EA200600605A1 (ru) Перегруппированные пентанолы, способ их получения и их применение в качестве противовоспалительных средств
GT200400188A (es) 5-arilpirimidinas como agentes anticancerigenos
CR9472A (es) Derivados de aminoacidos
DE60306636D1 (de) Wachstumhormonsekretionsförderer
MXPA05011289A (es) Compuestos de fosfato que tienen actividad inmunomoduladora.
PA8558901A1 (es) Nuevos compuestos hexaciclicos
UY28857A1 (es) 17a (alfa)-fluoroesteroides